Dallas, Texas, December 18, 2025
The Colossal Foundation has gained an additional $50 million in funding, totaling $100 million since its launch. This funding aims to enhance global conservation efforts against species extinction, with notable projects including cloning endangered wolves and developing vaccines for wildlife diseases. Established by Colossal Biosciences, the foundation is at the forefront of restoring biodiversity and protecting endangered species.
Dallas, Texas
The Colossal Foundation, the nonprofit arm of Colossal Biosciences, has secured an additional $50 million in funding, bringing its total to $100 million since its inception over a year ago. This significant investment aims to bolster global conservation efforts and combat species extinction.
Major Achievements in Conservation
In its inaugural year, the Colossal Foundation launched numerous projects across six continents, impacting over 40 species. Notable accomplishments include:
- Cloning the world’s first red “ghost” wolves to restore genetic diversity to America’s most endangered canid species.
- Accelerating the development of the world’s first mRNA vaccine for elephant endotheliotropic herpesvirus (EEHV), leading to successful vaccinations and recoveries in elephants at the Cincinnati Zoo.
- Deploying AI-powered acoustic monitoring across Yellowstone National Park to decode wolf communication, enhancing understanding of their behavior.
- Launching the Species Reintroduction Fund in partnership with Re:wild, supporting six flagship species across six countries.
- Committing $3 million to engineer chytrid-resistant amphibians in response to the deadliest wildlife pandemic in vertebrate history.
Background on the Colossal Foundation
Established to deploy Colossal Biosciences’ breakthrough de-extinction technologies, the Colossal Foundation focuses on protecting wildlife, restoring ecosystems, and building a resilient genetic safety net for species worldwide. The recent funding will accelerate projects centered on critically endangered species, genetic rescue, wildlife monitoring, and rewilding efforts.
About Colossal Biosciences
Colossal Biosciences is a biotechnology company founded in 2021, dedicated to de-extinction projects aimed at resurrecting extinct species such as the woolly mammoth, the dodo bird, and the Tasmanian tiger. Utilizing advanced gene-editing technologies, the company seeks to restore biodiversity and address the extinction crisis. As of January 2025, Colossal Biosciences has raised a total of $435 million, achieving a valuation of $10.2 billion.
Recent Developments
In January 2025, Colossal Biosciences secured $200 million in Series C funding, bringing its valuation to $10.2 billion. This funding is intended to expand the company’s de-extinction projects and accelerate the development of genetic engineering technologies with broader applications in species preservation and human healthcare.
Looking Ahead
The Colossal Foundation’s recent funding boost is expected to significantly enhance global conservation initiatives, contributing to the preservation of biodiversity and the restoration of ecosystems worldwide.
FAQ
What is the Colossal Foundation?
The Colossal Foundation is the nonprofit arm of Colossal Biosciences, dedicated to deploying de-extinction technologies to protect wildlife, restore ecosystems, and build a resilient genetic safety net for species worldwide.
How much funding has the Colossal Foundation secured?
The Colossal Foundation has secured a total of $100 million in funding since its inception over a year ago, with the most recent $50 million raised to bolster global conservation efforts.
What are some of the Colossal Foundation’s major achievements?
The Colossal Foundation has achieved several milestones, including cloning the world’s first red “ghost” wolves, accelerating the development of an mRNA vaccine for elephant endotheliotropic herpesvirus (EEHV), deploying AI-powered acoustic monitoring across Yellowstone National Park to decode wolf communication, launching the Species Reintroduction Fund in partnership with Re:wild, and committing $3 million to engineer chytrid-resistant amphibians.
What is Colossal Biosciences?
Colossal Biosciences is a biotechnology company founded in 2021, dedicated to de-extinction projects aimed at resurrecting extinct species such as the woolly mammoth, the dodo bird, and the Tasmanian tiger. Utilizing advanced gene-editing technologies, the company seeks to restore biodiversity and address the extinction crisis.
What recent developments have occurred with Colossal Biosciences?
In January 2025, Colossal Biosciences secured $200 million in Series C funding, bringing its valuation to $10.2 billion. This funding is intended to expand the company’s de-extinction projects and accelerate the development of genetic engineering technologies with broader applications in species preservation and human healthcare.
Key Features
| Feature | Description |
|---|---|
| Colossal Foundation’s Total Funding | $100 million |
| Major Achievements | Cloning red “ghost” wolves, developing EEHV vaccine, AI monitoring of wolf communication, Species Reintroduction Fund, chytrid-resistant amphibians |
| Colossal Biosciences’ Valuation | $10.2 billion |
| Recent Funding | $200 million in Series C funding |
Deeper Dive: News & Info About This Topic
HERE Resources
Base Power Raises $1 Billion for Texas Grid Renovation
Author: STAFF HERE DALLAS WRITER
The DALLAS STAFF WRITER represents the experienced team at HEREDallas.com, your go-to source for actionable local news and information in Dallas, Dallas County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as the State Fair of Texas, Deep Ellum Arts Festival, and Dallas International Film Festival. Our coverage extends to key organizations like the Dallas Regional Chamber and United Way of Metropolitan Dallas, plus leading businesses in telecommunications, aviation, and semiconductors that power the local economy such as AT&T, Southwest Airlines, and Texas Instruments. As part of the broader HERE network, including HEREAustinTX.com, HERECollegeStation.com, HEREHouston.com, and HERESanAntonio.com, we provide comprehensive, credible insights into Texas's dynamic landscape.
